The IPO is expected to raise CHF 75 million, with a potential increase to CHF 80 million through an over-allotment option. The company has received commitments from GSK and the AMR Action Fund.
Organizations Involved
GSK, AMR Action Fund
Founders
Marc Gitzinger, Dr. Sergio Lociuro
Company Description
BioVersys AG is a clinical-stage biopharmaceutical company dedicated to developing novel antibacterial treatments for life-threatening infections caused by multidrug-resistant (MDR) bacteria.
Market
Antibacterial treatments for life-threatening infections